{
    "clinical_study": {
        "@rank": "63891", 
        "arm_group": {
            "arm_group_label": "Chloroquine with Carboplatin/Gemcitabine", 
            "arm_group_type": "Experimental", 
            "description": "Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2).  Chloroquine dose is escalating."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety of chloroquine in combination with\n      carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid\n      tumors.\n\n      Also, the research study will be increasing the dose of chloroquine to find the highest dose\n      of chloroquine that can be given in combination with carboplatin and gemcitabine without\n      causing severe side effects."
        }, 
        "brief_title": "Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malignant Neoplasm", 
            "Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of a malignancy that is metastatic or unresectable\n             and for which either standard curative measures do not exist or are no longer\n             effective and carboplatin/gemcitabine is considered a reasonable treatment option\n             whether first line or acceptable and approved combination therapy.\n\n          -  Age >18 years of age.\n\n          -  Performance status less than or equal 2 (Karnofsky >60%)\n\n          -  Life expectancy of greater than 3 months.\n\n          -  Adequate labs\n\n          -  Measurable disease\n\n        Exclusion Criteria:\n\n          -  Current treatment with any other investigational agents.\n\n          -  Patients with untreated brain metastases\n\n          -  History of allergic reaction attributed to compounds of similar chemical or biologic\n             composition to chloroquine or other agents used in study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071537", 
            "org_study_id": "UCCI-EXP-13-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chloroquine with Carboplatin/Gemcitabine", 
                "description": "Dose is 50, 100, 150, and 200 mg per day cohorts.  It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.", 
                "intervention_name": "Chloroquine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Chloroquine Phosphate", 
                    "Aralen"
                ]
            }, 
            {
                "arm_group_label": "Chloroquine with Carboplatin/Gemcitabine", 
                "description": "Administered day 1 of each 21 day cycle for 4-6 cycles.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paraplatin", 
                    "CBDCA"
                ]
            }, 
            {
                "arm_group_label": "Chloroquine with Carboplatin/Gemcitabine", 
                "description": "Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine", 
                "Chloroquine diphosphate", 
                "Gemcitabine", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45267-0502"
                }, 
                "name": "University of Cincinnati Cancer Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Nagla Karim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Johm Morris, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sadia Benzaquin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pankaj Desai, MS, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James Driscol, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ahmed Khaled, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jun Ying, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors", 
        "overall_contact": {
            "email": "kastla@ucmail.uc.edu", 
            "last_name": "UC Cancer Institute Clinical Trials Office", 
            "phone": "513-584-7698"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Nagla Abdel-Karim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose of chloroquine when combined with Carboplatin/Gemcitabine", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071537"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Nagla Karim", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to Disease Progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Time of Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "University of Cincinnati", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}